Hospital
Community Mercy Health Partners
Community Mercy Health Partners was paid $8.81M by Medicaid between Jan 2018 and Dec 2024, across 132 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoCOMMUNITY MERCY HEALTH PARTNERS
URBANA, OH 43078
URBANA, OH 43078
33aNPI1144286352assigned 04/25/2006
33bProvider typeCritical Access Hospital
28Total paid$8.81M
24GClaims152,357
24DCodes billed132
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#9 of 26
Median peer was paid$5.33M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,460 | $667K | |
| 2019 | 13,293 | $689K | |
| 2020 | 9,199 | $1.44M | |
| 2021 | 9,998 | $1.14M | |
| 2022 | 12,395 | $735K | |
| 2023 | 57,693 | $2.14M | |
| 2024incomplete | 35,319 | $1.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 13,705 | 12,473 | $1.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 8,224 | 7,100 | $1.14M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 12% | 9,122 | 3,680 | $1.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 5,366 | 4,279 | $768K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 7.8% | 8,300 | 2,782 | $687K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 3.8% | 1,581 | 1,501 | $331K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 1,050 | 775 | $305K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.1% | 4,084 | 1,277 | $271K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 2,292 | 2,135 | $256K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 801 | 510 | $240K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 1,065 | 771 | $219K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.4% | 2,528 | 908 | $214K |
120 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 2,825 | $202K |
| 90832 | Psychotherapy session, about 30 minutes | 2.2% | 1,830 | $195K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 581 | $173K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.9% | 1,495 | $171K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,036 | $121K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 1,032 | $99K |
| 80053 | Comprehensive metabolic panel | <1% | 9,052 | $62K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 468 | $57K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 653 | $36K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 177 | $36K |
| 80305 | <1% | 4,956 | $22K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,041 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 139 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 932 | $16K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,852 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,793 | $14K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 314 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 310 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 652 | $11K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 406 | $9K |
| 80061 | Lipid panel | <1% | 708 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 82 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,132 | $8K |
| 97162 | <1% | 148 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 170 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 562 | $6K |
| 80320 | <1% | 562 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,660 | $4K |
| 83735 | <1% | 1,376 | $4K | |
| 71250 | <1% | 75 | $4K | |
| H2020 | Therapeutic behavioral services, per diem | <1% | 32 | $3K |
| 84439 | <1% | 272 | $3K | |
| 73630 | <1% | 244 | $3K | |
| 84484 | <1% | 2,326 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,723 | $3K |
| 85027 | <1% | 609 | $3K | |
| 73130 | <1% | 203 | $2K | |
| 81001 | <1% | 4,425 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,551 | $2K |
| 96367 | <1% | 43 | $2K | |
| 94060 | <1% | 12 | $2K | |
| 73030 | <1% | 96 | $2K | |
| 76536 | <1% | 13 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 77 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 763 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,450 | $2K |
| 73562 | <1% | 153 | $1K | |
| 90837 | Psychotherapy session, about an hour | <1% | 24 | $1K |
| 73610 | <1% | 162 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12 | $1K |
| 82570 | <1% | 147 | $1K | |
| 83880 | <1% | 707 | $1K | |
| 83690 | <1% | 2,260 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 30 | $1K |
| 81003 | <1% | 1,009 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 797 | $1K |
| 72100 | <1% | 27 | $999.78 | |
| 83605 | <1% | 1,290 | $972.88 | |
| 82607 | <1% | 51 | $922.76 | |
| 84100 | <1% | 185 | $911.98 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,425 | $874.06 |
| 94729 | <1% | 12 | $826.22 | |
| 83540 | <1% | 77 | $740.54 | |
| 85610 | <1% | 824 | $706.27 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 568 | $673.49 |
| 87070 | <1% | 41 | $635.32 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,816 | $589.93 |
| 82746 | <1% | 49 | $580.17 | |
| 94727 | <1% | 12 | $517.38 | |
| 96376 | <1% | 471 | $508.62 | |
| 82962 | <1% | 685 | $450.98 | |
| 87186 | <1% | 236 | $424.29 | |
| 81025 | <1% | 881 | $368.67 | |
| 84156 | <1% | 53 | $349.38 | |
| 87040 | <1% | 650 | $345.93 | |
| 85730 | <1% | 161 | $295.88 | |
| 90715 | <1% | 18 | $268.41 | |
| 82728 | <1% | 14 | $254.15 | |
| 83550 | <1% | 26 | $253.97 | |
| 82248 | <1% | 55 | $224.91 | |
| 84702 | <1% | 126 | $215.46 | |
| 87081 | <1% | 291 | $210.79 | |
| 85652 | <1% | 36 | $193.34 | |
| 87077 | <1% | 256 | $181.64 | |
| 86140 | <1% | 21 | $151.98 | |
| 84703 | <1% | 355 | $138.38 | |
| 87430 | <1% | 304 | $114.22 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 848 | $106.13 |
| 73502 | <1% | 21 | $101.71 | |
| 73110 | <1% | 12 | $93.05 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 22 | $60.53 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,870 | $51.01 |
| 85379 | <1% | 101 | $49.66 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 17 | $45.30 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 27 | $39.45 |
| 80329 | <1% | 140 | $30.59 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,937 | $23.70 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 22 | $19.44 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 545 | $18.06 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 84 | $15.95 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 40 | $15.31 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 135 | $11.90 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 229 | $5.61 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 123 | $5.52 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 210 | $1.95 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 46 | $1.24 |
| 85007 | 0% | 30 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 32 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 110 | $0.00 |
| 80179 | 0% | 27 | $0.00 | |
| 80143 | 0% | 29 | $0.00 | |
| 94664 | 0% | 22 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 45 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 13 | $0.00 |
| 94761 | 0% | 169 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 14 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 65 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 15 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 30 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.